• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

原胶原蛋白 C 蛋白酶增强蛋白是胶质母细胞瘤的一个预后因素，通过调节多种与肿瘤相关的通路和免疫微环境促进胶质母细胞瘤的发展。

Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.

机构信息

Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221104548. doi: 10.1177/03946320221104548.

DOI:10.1177/03946320221104548
PMID:35609253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9158419/
Abstract

OBJECTIVES

Glioma is a common type of brain tumor with high incidence and mortality rates. Procollagen C-protease enhancer protein (PCOLCE) has been shown to regulate tumor growth and metastasis in several cancers. However, the role of PCOLCE in glioma is unknown. This study aims to assess the association between PCOLCE and prognosis of glioma, and investigated the potential mechanisms.

METHODS

The prognostic value of PCOLCE was determined using data from nine publicly available glioma cohorts. We also investigated the relationship between PCOLCE and glioma immune microenvironment and predicted response to immunotherapy based on the expression levels of PCOLCE. The potential roles of PCOLCE in glioma were also explored and validated in cell experiment.

RESULTS

Survival analysis suggested that high-PCOLCE expression was associated with poor prognosis in glioma. Upregulation of PCOLCE enhanced an immune suppressive microenvironment in glioma by regulating immunocyte infiltration and Cancer-Immunity Cycle. Cox and ROC analysis revealed that PCOLCE was a prognostic factor for glioma and could be used to predict survival of the patients. Patients with low-PCOLCE expression were more likely to respond to Immunotherapy with ICI (immune checkpoint inhibitor) and survive longer. Enrichment analysis showed that PCOLCE was associated with multiple tumor-related pathways. Finally, we demonstrated that the knockdown of PCOLCE inhibited glioma development by regulating cell cycle and promoting apoptosis in in vitro experiments.

CONCLUSION

PCOLCE promotes glioma progression by regulating multiple tumor-related pathways and immune microenvironment and can be used as a prognostic factor for glioma.

摘要

目的

脑胶质瘤是一种常见的脑肿瘤，具有较高的发病率和死亡率。脯氨酰寡肽酶增强子蛋白（PCOLCE）已被证明在多种癌症中调节肿瘤生长和转移。然而，PCOLCE 在脑胶质瘤中的作用尚不清楚。本研究旨在评估 PCOLCE 与脑胶质瘤预后的关系，并探讨其潜在机制。

方法

使用来自 9 个公开可用的脑胶质瘤队列的数据确定 PCOLCE 的预后价值。我们还根据 PCOLCE 的表达水平研究了 PCOLCE 与脑胶质瘤免疫微环境的关系以及对免疫治疗的反应预测。还在细胞实验中探索和验证了 PCOLCE 在脑胶质瘤中的潜在作用。

结果

生存分析表明，高 PCOLCE 表达与脑胶质瘤预后不良相关。PCOLCE 的上调通过调节免疫细胞浸润和癌症免疫循环，增强了脑胶质瘤中的免疫抑制微环境。Cox 和 ROC 分析显示，PCOLCE 是脑胶质瘤的预后因素，可用于预测患者的生存情况。PCOLCE 低表达的患者对免疫治疗（ICI，免疫检查点抑制剂）更敏感，存活时间更长。富集分析表明，PCOLCE 与多种肿瘤相关通路有关。最后，我们在体外实验中证明，通过调节细胞周期和促进细胞凋亡，敲低 PCOLCE 可抑制脑胶质瘤的发展。

结论

PCOLCE 通过调节多种肿瘤相关通路和免疫微环境促进脑胶质瘤的进展，可以作为脑胶质瘤的预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/4668e35f6a8e/10.1177_03946320221104548-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/fa7cc7dd60c1/10.1177_03946320221104548-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/98f5943b272b/10.1177_03946320221104548-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d22456aff981/10.1177_03946320221104548-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/7e2757697b54/10.1177_03946320221104548-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d2d063e7b0f7/10.1177_03946320221104548-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/1531a3bba46b/10.1177_03946320221104548-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/76a6736993e4/10.1177_03946320221104548-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/0d48c85adf25/10.1177_03946320221104548-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d7af86fc5824/10.1177_03946320221104548-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/349b75d730c1/10.1177_03946320221104548-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/4668e35f6a8e/10.1177_03946320221104548-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/fa7cc7dd60c1/10.1177_03946320221104548-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/98f5943b272b/10.1177_03946320221104548-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d22456aff981/10.1177_03946320221104548-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/7e2757697b54/10.1177_03946320221104548-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d2d063e7b0f7/10.1177_03946320221104548-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/1531a3bba46b/10.1177_03946320221104548-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/76a6736993e4/10.1177_03946320221104548-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/0d48c85adf25/10.1177_03946320221104548-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/d7af86fc5824/10.1177_03946320221104548-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/349b75d730c1/10.1177_03946320221104548-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e60c/9158419/4668e35f6a8e/10.1177_03946320221104548-fig11.jpg

相似文献

1
Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.原胶原蛋白 C 蛋白酶增强蛋白是胶质母细胞瘤的一个预后因素，通过调节多种与肿瘤相关的通路和免疫微环境促进胶质母细胞瘤的发展。
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221104548. doi: 10.1177/03946320221104548.
2
Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients.前胶原C蛋白酶增强蛋白对胶质瘤患者预后的预测价值。
Heliyon. 2024 Mar 17;10(6):e28089. doi: 10.1016/j.heliyon.2024.e28089. eCollection 2024 Mar 30.
3
High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.PCOLCE 基因高表达提示患者预后不良，并与胶质瘤的免疫浸润有关。
Sci Rep. 2023 Mar 7;13(1):3820. doi: 10.1038/s41598-023-30413-5.
4
Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.前胶原C蛋白酶增强蛋白通过激活ERK信号促进胶质瘤生长。
Asia Pac J Clin Oncol. 2025 Feb;21(1):48-57. doi: 10.1111/ajco.14127. Epub 2024 Oct 15.
5
A pan-cancer analysis of the oncogenic role of procollagen C-endopeptidase enhancer (PCOLCE) in human.人类前胶原 C 端肽酶增强子（PCOLCE）在多种癌症中的致癌作用的泛癌症分析。
Medicine (Baltimore). 2022 Dec 30;101(52):e32444. doi: 10.1097/MD.0000000000032444.
6
Up-regulation of PCOLCE by TWIST1 promotes metastasis in Osteosarcoma.TWIST1 上调 PCOLCE 促进骨肉瘤转移。
Theranostics. 2019 Jun 9;9(15):4342-4353. doi: 10.7150/thno.34090. eCollection 2019.
7
STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.STEAP3 是一种预后生物标志物，通过调节免疫微环境和 PI3K-AKT 通路促进胶质瘤的进展。
Cancer Biomark. 2023;38(4):505-522. doi: 10.3233/CBM-230217.
8
Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response.对胶质瘤中肿瘤相关巨噬细胞（TAMs）标记基因进行综合分析以预测预后和免疫治疗反应。
Mol Immunol. 2022 Apr;144:78-95. doi: 10.1016/j.molimm.2022.02.012. Epub 2022 Feb 21.
9
to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma.评估脑胶质瘤的肿瘤免疫微环境与临床预后。
Front Immunol. 2021 Apr 6;12:648416. doi: 10.3389/fimmu.2021.648416. eCollection 2021.
10
Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.基于人线粒体核糖体 RNA 修饰的分类有助于区分胶质瘤患者的预后和免疫治疗反应。
Front Immunol. 2021 Sep 9;12:722479. doi: 10.3389/fimmu.2021.722479. eCollection 2021.

引用本文的文献

1
Exploring Molecular Alterations in Breast Cancer Among Indian Women Using Label-Free Quantitative Serum Proteomics.利用无标记定量血清蛋白质组学探索印度女性乳腺癌中的分子改变
Biochem Res Int. 2024 Nov 28;2024:5584607. doi: 10.1155/bri/5584607. eCollection 2024.
2
Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.前胶原C蛋白酶增强蛋白通过激活ERK信号促进胶质瘤生长。
Asia Pac J Clin Oncol. 2025 Feb;21(1):48-57. doi: 10.1111/ajco.14127. Epub 2024 Oct 15.
3
Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients.

本文引用的文献

1
Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood.分析人类神经胶质瘤相关共抑制免疫检查点在神经胶质瘤微环境和外周血中的作用。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211056505. doi: 10.1177/20587384211056505.
2
Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma.STEAP 家族对胶质瘤患者生存、免疫微环境和治疗反应的预测潜能。
Int Immunopharmacol. 2021 Dec;101(Pt A):108183. doi: 10.1016/j.intimp.2021.108183. Epub 2021 Oct 11.
3
Establishment and validation of five autophagy-related signatures for predicting survival and immune microenvironment in glioma.
前胶原C蛋白酶增强蛋白对胶质瘤患者预后的预测价值。
Heliyon. 2024 Mar 17;10(6):e28089. doi: 10.1016/j.heliyon.2024.e28089. eCollection 2024 Mar 30.
4
Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration.芳基硫酸酯酶D是一种预后生物标志物，它通过JAK2/STAT3信号通路和M2巨噬细胞浸润促进胶质瘤细胞进展。
Front Oncol. 2023 Sep 12;13:1228426. doi: 10.3389/fonc.2023.1228426. eCollection 2023.
用于预测胶质瘤生存和免疫微环境的五个自噬相关特征的建立与验证
Genes Genomics. 2022 Jan;44(1):79-95. doi: 10.1007/s13258-021-01172-2. Epub 2021 Oct 5.
4
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.脑内给予 CTLA-4 和 PD-1 免疫检查点阻断单克隆抗体治疗复发性胶质母细胞瘤患者的 I 期临床试验
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002296.
5
MiR-137 inhibits the proliferation, invasion and migration of glioma via targeting to regulate EZH2.miR-137 通过靶向调控 EZH2 抑制神经胶质瘤的增殖、侵袭和迁移。
Genes Genomics. 2021 Oct;43(10):1157-1165. doi: 10.1007/s13258-021-01117-9. Epub 2021 Jun 23.
6
PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer.PCOLCE是胃癌中强有力的预后生物标志物且与免疫浸润相关。
Front Mol Biosci. 2020 Dec 18;7:544895. doi: 10.3389/fmolb.2020.544895. eCollection 2020.
7
Suppression of long non-coding RNA PCAT19 inhibits glioma cell proliferation and invasion, and increases cell apoptosis through regulation of MELK targeted by miR-142-5p.抑制长链非编码 RNA PCAT19 通过 miR-142-5p 靶向调控 MELK 抑制神经胶质瘤细胞增殖、侵袭并促进细胞凋亡。
Genes Genomics. 2020 Nov;42(11):1299-1310. doi: 10.1007/s13258-020-01003-w. Epub 2020 Sep 26.
8
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.恶性神经胶质瘤的新兴免疫疗法：从免疫基因组学到细胞治疗。
Neuro Oncol. 2020 Oct 14;22(10):1425-1438. doi: 10.1093/neuonc/noaa154.
9
Lung metastases share common immune features regardless of primary tumor origin.肺转移瘤具有共同的免疫特征，而与原发肿瘤的起源无关。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000491.
10
Th9 Cell Differentiation and Its Dual Effects in Tumor Development.Th9 细胞分化及其在肿瘤发展中的双重作用。
Front Immunol. 2020 May 20;11:1026. doi: 10.3389/fimmu.2020.01026. eCollection 2020.